Liver, Pancreas, and Biliary Tract: Clinical ReviewsShould Antihepatitis B Virus Core Positive or Antihepatitis C Virus Core Positive Subjects Be Accepted as Organ Donors for Liver Transplantation?Gallegos-Orozco, Juan F. MD*; Vargas, Hugo E. MD† Author Information *Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, Mexico †Division of Transplantation Medicine, Mayo Clinic Arizona, Phoenix, AZ Reprints: Hugo E. Vargas, MD, Division of Transplantation Medicine, Mayo Clinic Arizona, 5777 East Mayo Boulevard, Phoenix, AZ 85054 (e-mail: [email protected]). Received for publication February 9, 2006; accepted July 21, 2006 Journal of Clinical Gastroenterology 41(1):p 66-74, January 2007. | DOI: 10.1097/01.mcg.0000225636.60404.bf Buy Metrics Abstract Since the introduction of liver transplantation as a routine surgical procedure for the treatment of end-stage liver disease, there has been an increasing gap between the number of available grafts and the number of patients on the waiting list. This has led transplant centers to expand the donor pool by different means. One of them has been the introduction of living donor liver transplantation. Other strategies include using less than optimal allografts from deceased donors, the so-called marginal donors, which include the use of grafts from older subjects, livers with moderate amounts of steatosis, or from donors with markers of past or current infection with hepatitis viruses who have absent or minimal liver biochemical or histologic injury. In this review, we will focus on the current use of allografts from donors with antihepatitis B core antibody and/or antibodies against hepatitis C virus in cadaveric and living donor liver transplantation. © 2007 Lippincott Williams & Wilkins, Inc.